Valuation: Alamar Biosciences, Inc.

Market Cap 1.95B 1.69B 1.58B 1.45B 2.73B 185B 2.77B 18.52B 7.27B 92.76B 7.31B 7.15B 309B P/E 2026 *
-20.6x
P/E 2027 * -42x
Enterprise Value 1.77B 1.53B 1.43B 1.31B 2.47B 168B 2.51B 16.78B 6.59B 84.08B 6.63B 6.48B 280B EV / Sales 2026 *
15.6x
EV / Sales 2027 * 11.1x
Free-Float
73.32%
Yield 2026 *
-
Yield 2027 * -
1 day-0.88%
1 week+15.31%
Current month+10.80%
1 month+8.33%
3 months+17.57%
1 week 24.7
Extreme 24.7
29.3
1 month 23.32
Extreme 23.32
29.43
Current year 18.84
Extreme 18.845
29.43
1 year 18.84
Extreme 18.845
29.43
3 years 18.84
Extreme 18.845
29.43
5 years 18.84
Extreme 18.845
29.43
10 years 18.84
Extreme 18.845
29.43
Manager TitleAgeSince
Chief Operating Officer 63 2018-07-31
Chief Tech/Sci/R&D Officer - 2020-12-31
Chief Executive Officer 62 2018-06-30
Director TitleAgeSince
Chairman 62 2018-06-30
Director/Board Member 64 2020-04-30
Date Insider Type Main position Quantity % Market Cap.
4/16/26 Conversion

Chief Executive Officer

8,786,851 318.3919%
Change 5-day change 1-year change 3-year change Capi.($)
-0.88%+15.31% - - 1.96B
+0.38%+0.62%+24.36%+5.72% 214B
+0.16%+1.78%+0.47%-21.50% 140B
-0.40%+5.84%-21.65%+20.82% 133B
+3.27%+7.08%-52.97%-2.80% 69.19B
+0.39%+4.15%+12.72%+12.28% 51.28B
-0.36%+4.16%-14.57%-20.67% 50.43B
+0.16%+0.74%+23.02%+11.91% 39.85B
-0.08%+5.33%+42.15%+37.88% 39.27B
-0.35%+4.18%-21.67%+24.54% 32.32B
Average +0.23%+5.03%-0.91%+7.58% 77.09B
Weighted average by Cap. +0.35%+3.07%+0.68%+4.05%

Financials

2026 *2027 *
Net sales 113M 98.26M 92M 84.17M 159M 10.77B 161M 1.08B 422M 5.39B 425M 416M 17.94B 162M 141M 132M 120M 227M 15.41B 230M 1.54B 604M 7.72B 608M 595M 25.67B
Net income -73.16M -63.5M -59.45M -54.39M -103M -6.96B -104M -696M -273M -3.48B -275M -269M -11.59B -56.76M -49.27M -46.13M -42.2M -79.56M -5.4B -80.74M -540M -212M -2.7B -213M -208M -9B
Net Debt -182M -158M -148M -136M -256M -17.34B -259M -1.73B -680M -8.69B -685M -670M -28.9B -153M -133M -124M -114M -214M -14.52B -217M -1.45B -570M -7.27B -573M -561M -24.19B
Logo Alamar Biosciences, Inc.
Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications.
Employees
222
Date Price Change Volume
26-08-06 US$28.10 -0.88% 246,414
26-08-05 US$28.35 +4.57% 201,180
26-08-04 US$27.11 +0.15% 272,615
26-08-03 US$27.07 +6.74% 183,693
26-07-31 US$25.36 +1.16% 154,363
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
28.35USD
Average target price
31.80USD
Spread / Average Target
+12.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALMR Stock